Y-Intercept (HK)’s Bio-Rad Laboratories Class A BIO Stock Holding History

Y-Intercept (HK)’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-847	Closed	-$206K	–	1639
2025 Q1	$206K	Buy	+847	New	+$255K	0.01%	1046
2024 Q4	–	Sell	-6,679	Closed	-$2.23M	–	1200
2024 Q3	$2.23M	Buy	+6,679	New	+$2.12M	0.14%	183
2023 Q4	–	Sell	-3,150	Closed	-$1.13M	–	1237
2023 Q3	$1.13M	Buy	+3,150	New	+$1.22M	0.11%	275
2023 Q2	–	Sell	-1,047	Closed	-$502K	–	1279
2023 Q1	$502K	Buy	+1,047	New	+$490K	0.06%	528
2022 Q4	–	Sell	-3,793	Closed	-$1.58M	–	1008
2022 Q3	$1.58M	Buy	+3,793	New	+$1.89M	0.16%	192
2022 Q2	–	Sell	-1,871	Closed	-$1.05M	–	870
2022 Q1	$1.05M	Buy	+1,871	New	+$1.13M	0.24%	103
2021 Q4	–	Sell	-2,219	Closed	-$1.66M	–	588
2021 Q3	$1.66M	Buy	+2,219	New	+$1.66M	0.3%	92
2021 Q2	–	Sell	-585	Closed	-$330K	–	629
2021 Q1	$330K	Buy	+585	New	+$346K	0.09%	369

Other funds holding BIO

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

FPA

First Pacific Advisors El Segundo, California $8.09B AUM 21.95% 1-Year Est. Return

Y-Intercept (HK)'s BIO Position: Q2 2025 in Review

Y-Intercept (HK) sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2025, closing a stake of 847 shares — an estimated $206K sold.

Y-Intercept (HK) first reported a position in BIO in Q1 2021 and held it in 8 quarters. The position peaked at $2.23M in Q3 2024. 384 funds tracked by Wall St. Rank hold BIO as of Q2 2025.

Y-Intercept (HK) reported no remaining Bio-Rad Laboratories Class A position as of Q2 2025 after selling out during the quarter.
Y-Intercept (HK) sold 847 Bio-Rad Laboratories Class A shares in Q2 2025, an estimated $206K.
Y-Intercept (HK) first reported a position in Bio-Rad Laboratories Class A in Q1 2021 and held it in 8 quarters.
Y-Intercept (HK)'s Bio-Rad Laboratories Class A position peaked at $2.23M in Q3 2024.
384 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2025.

Based on Y-Intercept (HK)'s 13F filing for Q2 2025, filed 1 Aug 2025.